INVO Fertility, Inc.

INVO Fertility's wholly owned subsidiary, INVO Centers, completed the acquisition of 100% of HRCFG, its joint venture partner in the Alabama JV fertility clinic, for a total purchase price of $175,001. This acquisition allows INVO Fertility to consolidate the Alabama JV's accounts into its financial statements. Additionally, the company announced that it has resolved its non-compliance with Nasdaq's Timely Filing Rule by submitting its Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

INVO Fertility, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on July 23, 2026. Key proposals include the election of five directors and the ratification of its independent auditor. Significantly, the company is seeking approval to increase its authorized common stock from 50 million to 250 million shares, approve the issuance of common stock for inducement warrants, and increase shares available under its 2019 Stock Incentive Plan to 1 million. Additionally, shareholders will vote on a proposal to approve a potential future equity financing that could issue 20% or more of outstanding common stock at prices below the Nasdaq Official Closing Price.

INVO Fertility reported strong financial results for Q1 2026, with revenue increasing 23% to $2.0 million, driven by organic growth and the acquisition of Family Beginnings. The company significantly strengthened its balance sheet by eliminating all Series C-2 Preferred Stock and warrant liabilities, leading to a 108% increase in stockholders' equity to $15.0 million. Despite a net loss from continuing operations of $(5.5) million (which included a $3.8 million non-cash loss), the company improved its cash position and reduced total liabilities, positioning itself for future growth through its focused fertility strategy.

INVO Fertility, Inc. reported a net loss of $(5.54) million for Q1 2026 from continuing operations, a significant increase from $(1.49) million in Q1 2025. Total revenue grew by 23.09% to $2.02 million. The company's financial statements include a going concern warning, citing dependence on external financing to meet liquidity needs. Despite this, cash and cash equivalents increased to $4.90 million, partly due to $7.1 million from a warrant inducement. The company continues to focus on its fertility business, including clinic operations and INVOcell technology sales, after divesting most of NAYA Therapeutics in Q2 2025.

INVO Fertility, Inc. reported a 23% increase in revenue to $2,015,225 for the first quarter ended March 31, 2026, driven by organic growth and the acquisition of Family Beginnings. The company significantly strengthened its balance sheet by eliminating all Series C-2 Preferred Stock and warrant liabilities, leading to a 108% increase in stockholders' equity to $15.0 million and a 26% reduction in total liabilities. Despite these improvements, the net loss from continuing operations widened to $(5.5) million, primarily due to a non-cash loss on warrant fair value changes, and Adjusted EBITDA was $(1.26) million, attributed to investments in operational infrastructure for future expansion.

INVO Fertility, Inc. announced it will present at the Planet MicroCap Conference on June 17, 2026. The company furnished an investor presentation, attached as Exhibit 99.1 to its Form 8-K, which covers its current and long-term operations, performance, and industry conditions. The presentation was also made available on the "Investors" portion of its website on June 16, 2026.

INVO Fertility, Inc. filed an amendment to its Form 10-K, primarily to remove the incorporation by reference of its definitive proxy statement for Part III and to include updated certifications for Item 15 of Part IV. The amendment does not contain financial statements. The filing also details executive and director compensation for 2025, including salary, bonuses, and stock awards. Notably, CEO Steven Shum experienced a late filing of a Form 4. The company's Audit Committee composition and financial expert designation are also outlined.

INVO Fertility, Inc. announced it received a delinquency notice from Nasdaq on May 27, 2026, for non-compliance with timely filing requirements for its 2025 Annual Report on Form 10-K and Q1 2026 Quarterly Report on Form 10-Q. The company has since filed the 10-K on June 2, 2026, and is working to file the 10-Q, attributing delays to complex accounting matters. The notice does not immediately affect the stock's Nasdaq listing, and the company has until June 22, 2026, to submit a compliance plan, with a potential extension until October 13, 2026. Despite the filing issues, INVO highlighted recent positive developments including a $7.5 million financing and the acquisition of Family Beginnings.

INVO Fertility announced its fiscal year 2025 financial results, reporting a 5% increase in total revenue to $6.84 million and an improved net loss from continuing operations of $(5.3) million compared to $(7.7) million in FY2024. The company also highlighted significant balance sheet strengthening with $11.5 million in recent financing, the acquisition of Family Beginnings in Indiana, and expansion of its clinic network and intellectual property. Management expressed optimism for future growth through organic initiatives and strategic acquisitions.

INVO Fertility, Inc. (IVF) filed its 10-K, detailing recent business developments including the acquisition of Family Beginnings, a fertility clinic, for $760,000. The company is facing Nasdaq non-compliance for late filings of its 10-K and 10-Q. Significant corporate actions include a 1-for-5 reverse stock split, a warrant inducement transaction raising $7.5 million, and an increase in authorized shares. The company also settled a litigation with Dr. Elizabeth Pritts for $6 million and divested a majority stake in NAYA Therapeutics.